Shared on 30 Aug 25
Fair value Decreased 2.22%Despite upgraded revenue growth forecasts and a sharply lower future P/E multiple, analysts have reduced their fair value estimate for Clinuvel Pharmaceuticals, lowering the consensus price target from A$24.42 to A$22.45. Valuation Changes Summary of Valuation Changes for Clinuvel Pharmaceuticals The Consensus Analyst Price Target has fallen from A$24.42 to A$22.45.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 12%AnalystConsensusTarget has decreased revenue growth from 25.2% to 9.5%, decreased profit margin from 43.2% to 38.0% and increased future PE multiple from 21.3x to 32.0x.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Decreased 8.05%AnalystConsensusTarget has increased revenue growth from 18.6% to 25.2% and decreased future PE multiple from 25.9x to 21.2x.